Stable liquid IL-1 antagonist formulations
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 2, 2010
Grant Date -
Aug 7, 2008
app pub date -
Mar 14, 2008
filing date -
Aug 17, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion proteins having an amino acid sequence of SEQ ID NO: 10. Stable liquid formulations made with and without sodium chloride, and made with phosphate or histidine buffer, are provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully